Literature DB >> 11375945

Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma.

N S Buttar1, K K Wang, T J Sebo, D M Riehle, K K Krishnadath, L S Lutzke, M A Anderson, T M Petterson, L J Burgart.   

Abstract

BACKGROUND & AIMS: The identification of any high-grade dysplasia (HGD) in Barrett's esophagus has been considered to be an indication for esophagectomy because of the increased risk of cancer. The aim of this study was to determine if a limited extent of HGD has the same potential for cancer as diffuse HGD.
METHODS: A retrospective cohort study was performed to assess the risk of developing adenocarcinoma in relationship to the extent of HGD found on endoscopic surveillance. The extent of HGD was defined as focal if cytologic and/or architectural changes of HGD were limited to a single focus of 5 or fewer crypts and diffuse if more than 5 crypts were involved in a single biopsy specimen or if HGD involved more than one biopsy fragment. The relative risk of cancer was assessed using a Cox proportional hazard model, and cancer-free survival was determined using survival curves.
RESULTS: Sixty-seven patients with diffuse HGD and 33 with focal HGD satisfied selection criteria. Cancer-free survival rates at 1 and 3 years were 93% and 86% for focal HGD compared with 62% and 44% for diffuse HGD (P < 0.001). On univariate analysis, extent of HGD (relative risk, 5.36; 95% confidence interval, 1.84-15.56), nodularity on endoscopy (relative risk, 3.98; 95% confidence interval, 1.97-8.04), and lack of acid suppression (relative risk, 2.48; 95% confidence interval, 1.16-5.28) were associated with an increased risk of esophageal adenocarcinoma. Diffuse HGD had a 3.7-fold increase in the risk of esophageal cancer compared with focal HGD (P = 0.02) on multivariate analysis.
CONCLUSIONS: Patients with focal HGD are less likely to have cancer during the first year after diagnosis or on subsequent follow-up compared with diffuse HGD.

Entities:  

Mesh:

Year:  2001        PMID: 11375945     DOI: 10.1053/gast.2001.25111

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  86 in total

1.  Minichromosome maintenance (MCM) proteins may be pre-cancer markers.

Authors:  M R Alison; T Hunt; S J Forbes
Journal:  Gut       Date:  2002-03       Impact factor: 23.059

2.  [Barrett esophagus: epidemiology, incidence of carcinoma, need for screening].

Authors:  R Arnold; M Wied
Journal:  Internist (Berl)       Date:  2003-01       Impact factor: 0.743

3.  Ablative mucosectomy is the procedure of choice to prevent Barrett's cancer.

Authors:  H Barr
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

4.  Medical and endoscopic management of high-grade dysplasia in Barrett's esophagus.

Authors:  K K Wang; J M Tian; E Gorospe; J Penfield; G Prasad; T Goddard; M Wongkeesong; N S Buttar; L Lutzke; S Krishnadath
Journal:  Dis Esophagus       Date:  2012-03-12       Impact factor: 3.429

5.  Can extent of high grade dysplasia in Barrett's oesophagus predict the presence of adenocarcinoma at oesophagectomy?

Authors:  M S Dar; J R Goldblum; T W Rice; G W Falk
Journal:  Gut       Date:  2003-04       Impact factor: 23.059

6.  Antagonist: endoscopic surveillance of patients with Barrett's oesophagus.

Authors:  R J Playford
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

Review 7.  Early events during neoplastic progression in Barrett's esophagus.

Authors:  Brian J Reid
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

Review 8.  [Barrett's esophagus. An update].

Authors:  G B Baretton; D E Aust
Journal:  Pathologe       Date:  2012-02       Impact factor: 1.011

9.  Barrett's Esophagus: A Review of Biology and Therapeutic Approaches.

Authors:  Panteleimon Kountourakis; Jaffer A Ajani; Marta Davila; Jeffrey H Lee; Manoop S Bhutani; Julie G Izzo
Journal:  Gastrointest Cancer Res       Date:  2012-03

Review 10.  Guidelines for surgical treatment of gastroesophageal reflux disease.

Authors:  Dimitrios Stefanidis; William W Hope; Geoffrey P Kohn; Patrick R Reardon; William S Richardson; Robert D Fanelli
Journal:  Surg Endosc       Date:  2010-08-20       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.